Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir

scientific article

Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.ANTIVIRAL.2008.10.008
P698PubMed publication ID19028525

P2093author name stringBin Li
Maria Seifer
Ilaria Serra
April Patty
David N Standring
P433issue2
P921main subjecttenofovirQ155954
P304page(s)147-155
P577publication date2008-11-24
P1433published inAntiviral ResearchQ4775352
P1476titleTelbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir
P478volume81

Reverse relations

cites work (P2860)
Q33711399A Review of Antiviral Use for the Treatment of Chronic Hepatitis B Virus Infection in Pregnant Women
Q34036018A cutting-edge view on the current state of antiviral drug development
Q37768591A review of oral antiretroviral therapy for the treatment of chronic hepatitis B.
Q41705394Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production
Q28282376Antiviral drug resistance: mechanisms and clinical implications
Q37255008Antiviral resistance and hepatitis B therapy
Q36467514Antiviral therapies: focus on hepatitis B reverse transcriptase
Q34223779Antiviral treatment of chronic hepatitis B virus (HBV) infections
Q37357573Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus
Q33677072Discovery and Development of Anti-HBV Agents and Their Resistance
Q48053718Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogue-untreated and -treated patients with chronic hepatitis B in a hospital in China
Q36765571Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naïve chronic HBV patients.
Q39213627Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains
Q39649139Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains
Q38219020Molecular diagnosis and treatment of drug-resistant hepatitis B virus
Q37620354Monotherapy versus combination therapy for the treatment of chronic hepatitis B.
Q28972486Safety and efficacy of telbivudine for the treatment of chronic hepatitis B
Q37775959Safety evaluation of telbivudine
Q37788209Telbivudine: a review of its use in compensated chronic hepatitis B.
Q37779093Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses
Q42159733Tenofovir rescue regimen following prior suboptimal response to entecavir and adefovir combination therapy in chronic hepatitis B patients exposed to multiple treatment failures
Q37247742Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates
Q33940140Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations

Search more.